{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:36:00Z","timestamp":1777646160333,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100011019","name":"National Research, Development and Innovation Office","doi-asserted-by":"crossref","award":["NKFI K105132"],"award-info":[{"award-number":["NKFI K105132"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12253-018-0466-9","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T03:30:40Z","timestamp":1537155040000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-1853","authenticated-orcid":false,"given":"T\u00edmea","family":"Balatoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lad\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kata","family":"Czirbesz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitta","family":"P\u00e1ncz\u00e9l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Bence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanda","family":"Pl\u00f3t\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Liszkay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"466_CR1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998\u20131012","journal-title":"N Engl J Med"},{"key":"466_CR2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/era.09.25","volume":"9","author":"SS Agarwala","year":"2009","unstructured":"Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587\u2013595","journal-title":"Expert Rev Anticancer Ther"},{"key":"466_CR3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"466_CR4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889\u20131894","journal-title":"J Clin Oncol"},{"key":"466_CR5","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlik AC et al (2015) Nivolumab and ipilimumab versus ipiliumab in untreated melanoma. N Engl J Med 372:2006\u20132017","journal-title":"N Engl J Med"},{"key":"466_CR6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:522\u2013530","journal-title":"Lancet Oncol"},{"key":"466_CR7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","volume":"116","author":"GY Ku","year":"2010","unstructured":"Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116:1767\u20131775","journal-title":"Cancer"},{"key":"466_CR8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-010-0958-2","volume":"60","author":"AM Giacomo Di","year":"2011","unstructured":"Di Giacomo AM, Danielli R, Calabro L, Bertocci E, Nannicini C, Giannarelli D et al (2011) Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 60:467\u2013477","journal-title":"Cancer Immunol Immunother"},{"key":"466_CR9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00262-013-1418-6","volume":"62","author":"AM Giacomo Di","year":"2013","unstructured":"Di Giacomo AM, Calabro L, Danielli R et al (2013) Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg\/kg within an expanded access programme. Cancer Immunol Immunother 62:1021\u20131028","journal-title":"Cancer Immunol Immunother"},{"key":"466_CR10","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","volume":"24","author":"J Delyon","year":"2013","unstructured":"Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24:1697\u20131703","journal-title":"Ann Oncol"},{"key":"466_CR11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CJI.0b013e31828eed39","volume":"36","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Li\u00e9nard D, Marmol VD, Neyns B (2013) Single-center experience with ipilimumab in an expanded access program for patients with pre-treated advanced melanoma. J Immunother 36:215\u2013222","journal-title":"J Immunother"},{"key":"466_CR12","first-page":"449","volume":"63","author":"S Kelderman","year":"2014","unstructured":"Kelderman S, Heemskerk B, van Tinteren H, van den Brom R, Hospers GA, van den Eertwegh A, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63:449\u2013458","journal-title":"Cancer Immunol Immunother"},{"key":"466_CR13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","volume":"63","author":"E Simeone","year":"2014","unstructured":"Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Carac\u00f2 C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA (2014) Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 63:675\u2013683","journal-title":"Cancer Immunol Immunother"},{"key":"466_CR14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/CMR.0000000000000108","volume":"24","author":"A Berrocal","year":"2014","unstructured":"Berrocal A, Arance A, Lopez Martin JA, Soriano V, Mu\u00f1oz E, Alonso L, Espinosa E, Lopez Criado P, Valdivia J, Martin Algarra S, Spanish Melanoma Group (2014) Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res 24:577\u2013583","journal-title":"Melanoma Res"},{"key":"466_CR15","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ejca.2015.09.007","volume":"51","author":"S Diem","year":"2015","unstructured":"Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J (2015) Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer 51:2785\u20132791","journal-title":"Eur J Cancer"},{"key":"466_CR16","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2015.180","volume":"112","author":"PF Ferrucci","year":"2015","unstructured":"Ferrucci PF, Gandini S, Battaglia A, Alfieri S, di Giacomo AM, Giannarelli D, Cappellini GCA, de Galitiis F, Marchetti P, Amato G, Lazzeri A, Pala L, Cocorocchio E, Martinoli C (2015) Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 112:1904\u20131910","journal-title":"Br J Cancer"},{"key":"466_CR17","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V (2015) Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 21:5453\u20135459","journal-title":"Clin Cancer Res"},{"key":"466_CR18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/cr.2015.3","volume":"25","author":"D Hannani","year":"2015","unstructured":"Hannani D, Vetizou M, Enot D et al (2015) Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25:208\u2013224","journal-title":"Cell Res"},{"key":"466_CR19","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.ejca.2015.06.130","volume":"51","author":"S Valpione","year":"2015","unstructured":"Valpione S, Martinoli C, Fava P, Mocellin S, Campana LG, Quaglino P, Ferrucci PF, Pigozzo J, Astrua C, Testori A, Chiarion-Sileni V (2015) Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. Eur J Cancer 51:2086\u20132094","journal-title":"Eur J Cancer"},{"key":"466_CR20","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/cam4.878","volume":"5","author":"L Khoja","year":"2016","unstructured":"Khoja L, Atenafu EG, Templeton A, Qye Y, Chappell MA, Saibil S, Hogg D, Butler MO, Joshua AM (2016) The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med 5:2792\u20132799","journal-title":"Cancer Med"},{"key":"466_CR21","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Geukes Foppen M et al (2016) Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22:2908\u20132918","journal-title":"Clin Cancer Res"},{"key":"466_CR22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjd.14155","volume":"174","author":"J Zaragoza","year":"2016","unstructured":"Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H, Machet L (2016) High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol 174:146\u2013151","journal-title":"Br J Dermatol"},{"key":"466_CR23","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043\u20136053","journal-title":"J Clin Oncol"},{"key":"466_CR24","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681\u20136688","journal-title":"Clin Cancer Res"},{"key":"466_CR25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954","journal-title":"Nature"},{"key":"466_CR26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molonc.2007.12.003","volume":"1","author":"A Platz","year":"2008","unstructured":"Platz A, Egyhazi S, Ringborg U, Hansson J (2008) Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenic subclass and body site. Mol Oncol 1:394\u2013405","journal-title":"Mol Oncol"},{"key":"466_CR27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","volume":"3","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA (2015) Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 3:288\u2013295","journal-title":"Cancer Immunol Res"},{"key":"466_CR28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1479-5876-12-116","volume":"12","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, del Vecchio M, di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo M, Guida M, Marconcini R, Mandal\u00e0 M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P (2014) Clinical experience with ipilimumab 3 mg\/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 12:116","journal-title":"J Transl Med"},{"key":"466_CR29","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bonsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"466_CR30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459\u2013465","journal-title":"Lancet Oncol"},{"key":"466_CR31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-014-1400-y","volume":"118","author":"P Queirolo","year":"2014","unstructured":"Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, del Vecchio M, di Guardo L, Maio M, di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neuro-Oncol 118:109\u2013116","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"466_CR32","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","volume":"2","author":"S Ugurel","year":"2007","unstructured":"Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A et al (2007) B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2(2):e236","journal-title":"PLoS One"},{"issue":"16","key":"466_CR33","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob JA, Basset RL, Cs N, Curry JL, Joseph RW et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014\u20134023","journal-title":"Cancer"},{"issue":"4","key":"466_CR34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","volume":"24","author":"B Devitt","year":"2011","unstructured":"Devitt B, Liu W, Salemi R, Wolfe R, Kelly J et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24(4):666\u2013672","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"466_CR35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.2014.287","volume":"111","author":"MS Carlino","year":"2014","unstructured":"Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV (2014) Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer 111(2):292\u2013299","journal-title":"Br J Cancer"},{"issue":"2","key":"466_CR36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","volume":"17","author":"JA Ellehorst","year":"2011","unstructured":"Ellehorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229\u2013235","journal-title":"Clin Cancer Res"},{"key":"466_CR37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"466_CR38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88:218\u2013230","journal-title":"Crit Rev Oncol Hematol"},{"key":"466_CR39","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124","journal-title":"J Natl Cancer Inst"},{"key":"466_CR40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1517\/14712598.6.7.671","volume":"6","author":"CA Petrulio","year":"2006","unstructured":"Petrulio CA, Kim-Schulze S, Kaufman HL (2006) The tumor microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther 6:671\u2013684","journal-title":"Expert Opin Biol Ther"},{"key":"466_CR41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/mp1004228","volume":"8","author":"EA Vasievich","year":"2011","unstructured":"Vasievich EA, Huang L (2011) The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm 8:635\u2013641","journal-title":"Mol Pharm"},{"key":"466_CR42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bjc.6602702","volume":"93","author":"H Schmidt","year":"2005","unstructured":"Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H (2005) Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 93:273\u2013278","journal-title":"Br J Cancer"},{"key":"466_CR43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJ Gooden","year":"2011","unstructured":"Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105:93\u2013103","journal-title":"Br J Cancer"},{"key":"466_CR44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pcmr.12371","volume":"28","author":"A Lad\u00e1nyi","year":"2015","unstructured":"Lad\u00e1nyi A (2015) Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res 28:490\u2013500","journal-title":"Pigment Cell Melanoma Res"},{"key":"466_CR45","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.4049\/jimmunol.178.7.4222","volume":"178","author":"L Simson","year":"2007","unstructured":"Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, Smyth MJ, Parish CR (2007) Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 178:4222\u20134229","journal-title":"J Immunol"},{"key":"466_CR46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, H\u00e4mmerling GJ (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nat Immunol 16:609\u2013617","journal-title":"Nat Immunol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-018-0466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-018-0466-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-018-0466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T15:26:29Z","timestamp":1662045989000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-018-0466-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1007\/s12253-018-0466-9","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]},"assertion":[{"value":"7 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"T\u00edmea Balatoni has received speaker honoraria and financial support for attending symposia from Bristol-Myers Squibb, Merck Sharp & Dohme (MSD), Novartis, and Roche. Gabriella Liszkay is on the advisory board and has received honoraria for speaking at conferences as well as financial support for educational programs from Bristol-Myers Squibb, GlaxoSmithKline, MSD, Novartis, and Roche. Gitta P\u00e1ncz\u00e9l and Kata Czirbesz has received speaker honoraria from Bristol-Myers Squibb, MSD, Novartis, and Roche. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}